Recruiting
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
About this study
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
- Condition
- Metastatic Castration-Resistant Prostate Carcinoma
- Tested
- Non-Interventional Study
- Sponsor
- University of Michigan Rogel Cancer Center
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Metastatic Castration-Resistant Prostate Carcinoma
- \* 177Lu-617 PSMA treatment scheduled for mCRPC
- Clinically stable as determined by the nuclear medicine clinicians
- ≥ 18 years of age
- Willing and able to provide informed consent
Exclusion 1
- Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed
Where
1 site, 1 recruiting
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Potential match only. Final eligibility is determined by the study team.